PYC Therapeutics (ASX:PYC) Receives Approval for Dose Escalation in ADOA Clinical Trial
PYC Therapeutics (ASX:PYC) receives approval to escalate dosing in its ADOA clinical trial, advancing development of its PYC-001 drug candidate.
Category: Healthcare
4DMedical Limited (ASX:4DX) Partners with Olympus to Launch SeleCT™ Screening Campaign
4DMedical Limited (ASX:4DX) partners with Olympus to deploy AI-powered SeleCT™ Screening, enhancing COPD diagnosis and treatment.
Radiopharm Theranostics (ASX:RAD) Receives FDA Fast Track for RAD101
Radiopharm Theranostics (ASX:RAD) secures FDA Fast Track for RAD101, advancing its Phase 2 trial in brain metastases imaging.
Syntara Limited (ASX:SNT) Receives FDA Fast Track Designation for SNT-5505
Syntara Limited (ASX:SNT) secures FDA Fast Track for its myelofibrosis treatment SNT-5505, accelerating its development towards becoming a new standard of care.
Botanix Pharmaceuticals (ASX:BOT) Secures A$48M Debt Facility
Botanix Pharmaceuticals (ASX:BOT) secures A$48 million debt facility with Kreos Capital to support Sofdra™ commercialisation and platform expansion.
EBR Systems (ASX:EBR) Completes First US Commercial Implants of WiSE CRT System
EBR Systems (ASX:EBR) completes first US commercial implants of its WiSE CRT System, advancing towards market release and reimbursement in October 2025.
Mayne Pharma Group Limited (ASX:MYX) Updates on Scheme of Arrangement with Cosette
Mayne Pharma (ASX:MYX) updates investors on its Scheme of Arrangement with Cosette, addressing recent regulatory and contractual developments.
Invion Limited (ASX:IVX) Reports Positive Phase I/II Skin Cancer Trial Results
Invion Limited (ASX:IVX) reports positive safety and efficacy results in Phase I/II skin cancer trial, progressing to next study phase.
Noxopharm Limited (ASX:NOX) Receives Approval for HERACLES Clinical Trial
Noxopharm Limited (ASX:NOX) receives ethics approval for its innovative HERACLES clinical trial, advancing new treatments for chronic inflammatory diseases.
Emyria Limited (ASX:EMD) Reports Promising Six-Month PTSD Outcomes and MOU with ANU
Emyria Limited (ASX:EMD) reports promising six-month PTSD treatment outcomes and signs a strategic MOU with ANU to advance mental health research.